Description

Ruxolitinib Phosphate CAS NO 1092939-17-7 is the phosphate salt form of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and JAK 2 inhibitor. This active pharmaceutical ingredient (API) is critical for the development and manufacturing of targeted therapies for myeloproliferative neoplasms and other inflammatory conditions. It is primarily required by pharmaceutical companies, research institutions, and contract development and manufacturing organizations (CDMOs) engaged in oncology and immunology drug development.

Application

• Pharmaceutical API: Primary use as the active ingredient in the formulation of finished dosage forms, such as tablets, for the treatment of myelofibrosis and polycythemia vera.
• Oncology Research: A key reference standard and tool compound in preclinical and clinical research for studying JAK-STAT signaling pathways and their role in hematologic cancers.
• Drug Development: Serves as a critical intermediate in the development of new therapeutic agents targeting autoimmune diseases like rheumatoid arthritis and graft-versus-host disease (GVHD).
• GMP Manufacturing: Used in the commercial-scale, Good Manufacturing Practice (GMP) compliant production of approved medications, ensuring batch-to-batch consistency and regulatory compliance.
• Bioavailability Studies: The phosphate salt form is often utilized to improve the solubility and pharmacokinetic profile of the parent compound in formulation studies.

Basic Information

Product Name	Ruxolitinib Phosphate
CAS No.	1092939-17-7
Molecular Formula	C17H21N6O · H3PO4
Molecular Weight	446.37 g/mol (as free base phosphate salt)
Synonyms	Ruxolitinib phosphate salt; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; INCB018424 phosphate; Jakafi® (brand name drug substance); JAK1/JAK2 Inhibitor phosphate; INC424 phosphate
EINECS	Contact for details

Quality Control

Our Ruxolitinib Phosphate is manufactured under strict quality systems to meet the rigorous standards required for pharmaceutical applications. We offer material compliant with current Good Manufacturing Practices (cGMP) for use as an API. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles, ensuring traceability and regulatory readiness for our global clientele.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under inert conditions or in a desiccator to maintain stability and potency.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥98.5%
Water Content (KF)	≤0.5%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm
Related Substances (HPLC)	Individual impurity ≤0.5%; Total impurities ≤1.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.